Heol-D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the management of gastrointestinal disorders characterized by acid-related symptoms and motility disturbances. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric emptying and enhances gastrointestinal motility, thereby alleviating symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The sustained-release (SR) formulation of Heol-D ensures prolonged therapeutic plasma concentrations, optimizing symptom control and improving patient compliance by reducing dosing frequency. This combination therapy is particularly beneficial in patients requiring both acid suppression and prokinetic effects to manage complex gastrointestinal symptoms. Heol-D Capsule SR should be administered as prescribed by a healthcare professional, with consideration of contraindications such as hypersensitivity to either component, and caution in patients with cardiac arrhythmias or hepatic impairment. Regular monitoring is advised to assess therapeutic efficacy and detect potential adverse effects.